Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Patient plan: look up a medication list

SILODOSIN

All products: Limited Use (codes 351, 352)

Other products in the same Health Canada class (G04C, G04CA) — coverage varies; not interchangeable

  • Tamsulosin (Flomax CR Tab): general benefit, Not a benefit
  • Alfuzosin (Xatral): limited Use 351, 352
  • Dutasteride (Avodart): limited Use 384, 385
  • Finasteride (Propecia): limited Use 384, 385, Not a benefit

Sandoz Silodosin · DIN 02475421 · 4mg · capsule

Limited Use — Reason for Use code 351, 352 requiredMarketed · checked 2026-09-19
StatusLimited Use — Reason for Use code 351, 352 required
Write on scriptLU code 351, 352 (patient must meet the criteria below)
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Ontario Limited Use criteria — code 351, 352
Reason for Use code 351 For the management of benign prostatic hyperplasia where six weeks of treatment with other formulary alpha blockers (e.g. doxazosin, terazosin, tamsulosin) have been ineffective. Coverage limit: LU Authorization Period: Indefinite Reason for Use code 352 For the management of benign prostatic hyperplasia where other formulary alpha blockers (e.g. doxazosin, terazosin, tamsulosin) have produced intolerable side effects. Coverage limit: LU Authorization Period: Indefinite
1 brand, same coverage
Sandoz Silodosin · DIN 02475421 Manufacturer: Sandoz Canada Inc.; listing date 2021-03-29 Health Canada: Marketed since 2021-01-08 · brand SANDOZ SILODOSIN · ATC G04CA04 SILODOSIN · form Capsule · route Oral · ingredients SILODOSIN 4 MG · company Sandoz canada incorporated · schedule Prescription
Check this DIN again · Health Canada product record

Sandoz Silodosin: Formulary list price $0.4742/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.4742 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=96581 · Verify on the e-Formulary ↗ (DIN 02475421)

Source record
DIN 02475421: Sandoz Silodosin Raw flags: chronicUseMed=Y, sec12=Y, sec3=Y Item: 920000678; group id 958; item number 2275; lccId 00229; manufacturer id SDZ Source form: Cap; strength: 4mg Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $0.4742; ministry $0.4742 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02475421 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=96581
Interchangeable products
Auro-Silodosin · DIN 02478501 · $0.4742 Jamp Silodosin · DIN 02539519 · $0.4742 PMS-Silodosin · DIN 02517779 · $0.4742 Rapaflo · DIN 02361663 · not recorded
Shortage status: not checked (no credentials)
Other drugs in the same formulary class (92:00 UNCLASSIFIED THERAPEUTIC AGENTS) and how they are covered

Matched class: 92:00 UNCLASSIFIED THERAPEUTIC AGENTS

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: ALENDRONATE & CHOLECALCIFEROL, AZATHIOPRINE, CYCLOSPORINE, GLUCAGON RDNA ORIGIN, LANREOTIDE ACETATE, LEFLUNOMIDE, LEVODOPA & BENSERAZIDE, MYCOPHENOLATE SODIUM Some products covered without a code (check the product listing): ALENDRONATE, ALLOPURINOL, AMANTADINE HCL, BROMOCRIPTINE, CLOPIDOGREL BISULFATE, LEVODOPA & CARBIDOPA, MYCOPHENOLATE MOFETIL, OCTREOTIDE, RISEDRONATE SODIUM, ROPINIROLE, SELEGILINE HCL, TAMSULOSIN HCL 92:00 UNCLASSIFIED THERAPEUTIC AGENTS

TAMSULOSIN HCL

· 10 products · General benefit (9), Listed, not a benefit (1) · strengths: 0.4mg · ER Cap

ALFUZOSIN HYDROCHLORIDE

· 6 products · Limited Use, codes 351, 352 · strengths: 10mg · Prolong-Rel Tab

DUTASTERIDE

· 12 products · Limited Use, codes 384, 385 · strengths: 0.5mg · Cap

FINASTERIDE

· 23 products · Off-Formulary Interchangeable, not an ODB benefit (8), Limited Use, codes 384, 385 (15) · strengths: 1mg, 5mg · Tab

ALENDRONATE

· 28 products · Off-Formulary Interchangeable, not an ODB benefit (4), Listed, not a benefit (1), General benefit (23) · strengths: 5mg, 10mg, 70mg · Tab

ALENDRONATE & CHOLECALCIFEROL

· 6 products · General benefit · strengths: 70mg & 70mcg, 70mg & 140mcg · Tab

ALLOPURINOL

· 10 products · General benefit (6), Listed, not a benefit (4) · strengths: 100mg, 200mg, 300mg · Tab

AMANTADINE HCL

· 5 products · Listed, not a benefit (2), General benefit (3) · strengths: 100mg, 10mg/mL · Cap, O/L

AZATHIOPRINE

· 3 products · General benefit · strengths: 50mg · Tab

BROMOCRIPTINE

· 4 products · Listed, not a benefit (2), General benefit (2) · strengths: 5mg, 2.5mg · Cap, Tab

CLOPIDOGREL BISULFATE

· 19 products · General benefit (16), Off-Formulary Interchangeable, not an ODB benefit (3) · strengths: 75mg, 300mg · Tab

CYCLOSPORINE

· 8 products · General benefit · strengths: 10mg, 25mg, 50mg, 100mg, 100mg/mL · Cap, O/L Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 92:00 and 75 more
Full class listing Related classes: Same formulary class, not same indication: class membership alone does not establish equivalent uses.
Other drugs whose Health Canada label lists a similar indication: the signs and symptoms of benign prostatic hyperplasia
From Health Canada product monographs; label wording only, not a treatment recommendation. Matching is lexical and uses one held product label per generic; formulations and qualifying criteria may differ. No displayed matched alternative is a general benefit. ALFUZOSIN HYDROCHLORIDE · Limited Use, codes 351, 352 INDICATIONS AND CLINICAL USE XATRAL (alfuzosin hydrochloride) is indicated for:  Benign Prostatic Hyperplasia XATRAL is indicated for the treatment of the signs and symptoms of benign prostatic hyperplasia (BPH).  Acute Urinary Retention XATRAL is indicated as adjunctive therapy with urethral catheterization for Acute Urinary Retention related to BPH and management following catheter removal. PM: https://pdf.hres.ca/dpd_pm/00049054.PDF; date January 2, 2019; DIN 02245565; fetched 2026-09-10 Product monograph TADALAFIL · Off-Formulary Interchangeable, not an ODB benefit (72), Off-Formulary Interchangeable, not an ODB benefit; DIN status E (meaning unconfirmed); confirm discontinuation/availability with Health Canada (1) CIALIS is indicated for the treatment of the signs and symptoms of benign prostatic hyperplasia (BPH). PM: https://pdf.hres.ca/dpd_pm/00037181.PDF; date not captured; DIN 02248088; fetched 2026-09-10 Product monograph Coverage source: ON formulary extract 2026-08-26
What the Health Canada label says it is for
INDICATIONS AND CLINICAL USE Sandoz Silodosin (silodosin) is indicated for:  The treatment of the signs and symptoms of benign prostatic hyperplasia (BPH). Geriatrics (≥ 65 years of age): Silodosin has been found to be safe and effective when administered at therapeutic doses (8 mg once daily) to patients over the age of 65 years (see CLINICAL TRIALS section). Pediatrics (< 18 years of age): The safety and effectiveness of silodosin in pediatric patients have not been established. Sandoz Silodosin is not indicated for use in children (see WARNINGS AND PRECAUTIONS section). Women: The safety and effectiveness of silodosin in female patients have not been established. Sandoz Silodosin is not indicated for use in women (see WARNINGS AND PRECAUTIONS section). https://pdf.hres.ca/dpd_pm/00060987.PDF PM date: May 14, 2021 Source product: SANDOZ SILODOSIN; DIN 02475421; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.